Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve

adult Nigerians

Abdulfattah Adekunle Onifade¹, Adeola Fowotade², Sheu Kadiri Rahamon^{1*}, Victory Fabian Edem¹, Surajudeen Adebayo Yaqub¹, Olatunji Kadri Akande², Olatunbosun Ganiyu Arinola¹

¹Department of Immunology, College of Medicine, University of Ibadan, Nigeria. ²Biorepository Clinical Virology Laboratory, College of Medicine, University of Ibadan, Nigeria.

***Corresponding Author:** Sheu Kadiri Rahamon, Ph.D. Phone: +2348067420607 E-mail: adekunlesheu@rocketmail.com; sk.rahamon@mail1.ui.edu.ng

Article Type: Original Article

Conflict of Interest: Authors have no competing interest to declare.

Running Title: Anti-SARS-CoV-2 antibodies in vaccinated and vaccine naïve adults

Keywords: Immune response, SARS-CoV-2, Seroprevalence, Vaccine

Abstract

Background: Reports on the evaluation of immune responses to different COVID-19 vaccines are limited. Similarly, effects of age and gender have not been well explored as variables that could impact on the vaccine-induced antibody response. Therefore, seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians was determined in this study.

Methodology: A total of 141 adults were enrolled into this study. Presence or absence of SARS-CoV-2 infection was confirmed by real-time reverse-transcriptase polymerase-chain reaction (RT-PCR) assay on nasopharyngeal and oropharyngeal swab specimens. Anti-SARS-CoV-2 Specific IgG and IgM antibodies were qualitatively detected using a Rapid Diagnostic Test kit.

Results: Pre-vaccination, 77% of the study participants had never had PCR-confirmed COVID-19 test yet 66.7% of them were seropositive for SARS-CoV-2 antibodies. Of 111 COVID-19 vaccinated participants, 69.2% and 73.8% of them had SARS-CoV-2 specific IgG post-first and second doses of COVID-19 vaccine respectively. However, 23.1% and 21.4% of the participants who have had first and second doses respectively had no detectable anti-SARS-CoV-2 antibodies. The proportion of participants with SARS-CoV-2 specific IgG was insignificantly higher in those between the ages of $18 - 40$ years and $41 - 59$ years compared with individuals aged ≥60 years. No significant association was observed between gender and seropositivity for SARS-CoV-2 antibodies.

Conclusion: There is high SARS-CoV-2 antibody seroprevalence among Nigerian adults who never had PCR-confirmed COVID-19. Also, there is the need for anti-SARS-CoV-2 antibodies screening post vaccination as this could be essential in achieving herd immunity. Age and gender do not seem to have significant association with seropositivity.

Introduction

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout the world since October 2019 and is responsible for the Coronavirus disease 2019 (COVID-19), a new respiratory tract infection (1). The worldwide engagement to reduce the COVID-19 pandemic has led to the rapid development of diverse SARS-CoV-2 vaccines.

As of the 18th of March 2021, at least thirteen COVID-19 vaccines had received approval for different levels of use, while another twenty-seven were undergoing large-scale, Phase III, final randomized controlled trials (2). Yet, many more are still emerging (3). Since there is no generally accepted specific treatment for COVID-19, vaccination is still one of the most effective means of preventing the disease (4, 5). Kaur and Gupta (6) reported that COVID-19 vaccines are either based on the mechanism of active immunity or passive immunity. Those of active immunity include DNA vaccine (e.g. Inovio), RNA vaccine (e.g. Moderna, Pfizer), viral vector [e.g. Oxford/AstraZeneca, CanSino Biologics, Janssen (J & J), Gamalaya-Sputnik], viral subunit (e.g. Novavax, AdaptVac, Clover Biopharma), Live Attenuated (e.g. Codagenix), Inactivated Virus (e.g. SinoVac, SinoParm) , Virus Like Particles (VPL), Split Virus Vaccines (e.g. Flu Vaccines) and Ribonucleoprotein (RNP) Vaccine. On the other hand, those of passive immunity include monoclonal antibodies (e.g. bamlanivimab), polyclonal antibodies (e.g. regeneron and mRNA induced antibody) and convalescent plasma.

Despite the progress made by the vaccine development there are challenges of safe and effective vaccines, which need to be substantiated by laboratory findings. For the goal of global eradication to be achieved, 70% of all humans must receive the COVID-19 vaccine(7). In this regard, Nigeria aimed to vaccine 40% of its over 200 million people by the end of the year 2021 and hopes to achieve the 70% vaccination threshold for eliminating COVID-19

before the end of the year 2022 (8). As of 7 June 2022, a total of 11,854,673,610 vaccine doses have been administered globally (9). In Nigeria, as of 29 May 2022, about 30,680,510 (14.9% of the population) Nigerians have taken at least 1 dose while 20,096,868 (9.7% of the population) are fully vaccinated (10). Thus, the uptake of COVID-19 vaccine remains low in Nigeria.

Previous immunological studies on host immune responses during COVID-19 have contributed to the development of COVID-19 vaccines whose efficacy is yet to be fully reported. However, there is the dearth of evidence on SARS-CoV-2 infection-induced immunity compared to vaccine-induced immunity. It is however important to determine the antibody responses to vaccinated and unvaccinated persons in other to determine possibility of previous SARS-CoV-2 exposure or protection. During natural SARS-CoV-2 infection, the S and N proteins of SARS-CoV-2 have been identified as the primary antigens for antibody production (11). Other studies reported that symptomatic COVID-19 patients develop SARS-COV-2 antibodies (12) and waning begins after few months (13). It was reported that concentrations of these SARS-CoV-2 specific antibodies are crucial in determining roles of these antibodies as either protective or disease facilitating antibodies especially in approaches to vaccine design and immunization delivery (14). Following SARS-CoV-2 infection; naïve B cells are activated via antigen recognition and CD4⁺ T cells activation. This cascade of events results in production of antibodies and memory B cells. Avalanche of reports have shown that the majority of patients with SARS-CoV-2 infection seroconvert especially, to Sprotein within few days of onset of symptoms with viral-specific IgG, IgA and IgM developing simultaneously (15-19). In SARS-CoV-2, three types of seroconversion have been reported; IgM seroconversion earlier than IgG, IgG seroconversion earlier than IgM and synchronous seroconversion of IgM and IgG (15). The seroconversion for SARS-CoV-2 specific IgG antibodies occurred simultaneously or sequentially as IgA and IgM (20, 21).

However, the median time to seroconversion varies (22) as Iyer *et al*. (20) and Long *et al*. (15) reported that that the median time to seroconvesion is between 11 and 13 days postsymptom onset (PSO). Also, Röltgen *et al*. (21) reported that the seroconversion rates in hospitalized patients for anti-S receptor binding domain (RBD) IgM, IgG and IgA reached their maximum between 4 to 6 weeks PSO. Changes in the dynamics of SARS-CoV-2 specific antibodies as well as memory B and T cells have been well explored in the design of various vaccines against the infection and guided the advocacy for booster vaccines .

Host immunological responses to SARS-CoV-2 vaccines are scarce. Though it was reported that titers of neutralizing antibodies (nAbs) to SARSCoV-2, and the concentration of antibodies binding to spike or receptor-binding domain (RBD) are associated to vaccineinduced protection (22-25). Precise determination of how the immune system responds to vaccines compared to SARS-CoV-2 infection is of great concern. Therefore, understanding the natural immune responses induced by SARS-CoV-2or by vaccination is important for better assessment of protection against SARS-CoV-2 re-infection and vaccine response.

Materials and Methods

Study site

The study participants were consecutively enrolled from among adults seeking COVID-19 screening at the Biorepository Laboratory, College of Medicine, University of Ibadan and from among the general populace in Ibadan North Local Government Area of Oyo State, Nigeria.

Study Population

A total of 141 adults were enrolled into this study. Participants with past SARS-CoV-2 infection history and those without were those confirmed positive or otherwise, by real-time reverse-transcriptase polymerase-chain reaction (RT-PCR) assay on nasopharyngeal and oropharyngeal swab specimens following the World Health Organization (WHO) guideline (26). All the vaccinated participants had their vaccination at the Nigeria Centre for Disease Control (NCDC) approved centres and were enrolled into the study after at least, one month post vaccination.

Exclusion criteria

Participants with infections such as HIV or pulmonary tuberculosis were excluded from this study.

Ethical consideration

The study was conducted after obtaining approval from the University of Ibadan/University College Hospital (UI/UCH) Joint Ethics Review Committee (UI/EC/20/0233). Written informed consent was also obtained from the study participants.

Determination of SARS-CoV-2 specific IgM and IgG antibodies

SARS-CoV-2 specific antibodies were qualitatively detected using a commercially-available Rapid Diagnostic Test kit (Wuhan UNscience Biotechnology Company Limited, China). The kit works on the principle of lateral flow immunoassay and detects IgG and IgM antibodies to

SARS-CoV-2 in human whole blood, serum, or plasma. It has a clinical sensitivity of 98.511% (95% CI: 96.788% - 99.452%) and specificity of 88.208% (95% CI: 83.086% - 92.221%). The detection was carried out following the manufacturers' instruction.

Statistical Analysis

Statistical analysis was carried out using SPSS statistical software version 23.0 for windows. Chi-square test or Fischer's exact test, as appropriate, was used to determine the association between categorical variables. *P*-values less than 0.05 were considered as statistically significant.

Results

The gender and age groups of the study participants are shown in Table 1. The study participants were largely female and more than 50% of them were not older than 40 years.

Table 1: Gender and age of the study participants

As shown in Table 2, about 77% of the study participants were unsure of their COVID-19 history as they had never had COVID-19 PCR test done. The proportion of participants who had either the first or second dose of COVID-19 vaccine was higher than those who were not yet vaccinated. Over 90% of the participants had AstraZeneca vaccine administered (Table 2). Coincidentally, 7 (77.8%) of the 9 participants that took Moderna vaccine had detectable SARS-CoV-2 antibodies while 2 (22.2%) did not. Similarly, 77 (77.8%) of the 99 participants that took Astrazeneca vaccine had detectable SARS-CoV-2 antibodies while 22 (22.2%) did not.

	Number	Percentage (%)
COVID-19 History		
Previous PCR-confirmed infection	17	12.1
No history of PCR-confirmed infection	15	10.6
Never had COVID-19 test	109	77.3
Vaccine History		
Not yet vaccinated	33	23.4
Post first dose	65	46.1
Post second dose	42	29.8
Post booster dose	$\mathbf{1}$	0.7
Vaccine Type		
Astrazeneca	99	91.7
Moderna	9	8.3

Table 2: History of COVID-19 and vaccine uptake in the study participants

Responses to COVID-19 vaccine are contained in Table 3. Twenty (60.6%) participants who were not yet vaccinated were seropositive for SARS-CoV-2-specific IgG while 6.1% were seropositive for both SARS-CoV-2-specific IgG and IgM. As expected, post first and second doses of COVID-19 vaccine, 69.2% and 73.8% of the study participants had SARS-CoV-2 specific IgG. However, 7.7% of those who had taken first dose of the vaccine had a combination of IgM and IgG. Unexpectedly, 23.1% and 21.4% of the participants who have had first and second doses respectively, had no protective antibody to SARS-CoV-2. The only participant who has had the booster dose was seronegative (Table 3).

	Not yet vaccinated	PFD	PSD	PBD	N	X^2	P -value	
Seronegative	$11(33.3\%)$	$15(23.1\%)$	$9(21.4\%)$	(100.0%)	36	12.459	0.189	
IgM	$0(0.0\%)$	$0(0.0\%)$	$2(4.8\%)$	$0(0.0\%)$	$\overline{2}$			
IgG	$20(60.6\%)$	$45(69.2\%)$	31 (73.8%)	$0(0.0\%)$	96			
$IgM + IgG$	$2(6.1\%)$	$5(7.7\%)$	$0(0.0\%)$	$0(0.0\%)$	7			

Table 3: Association between seropositivity and vaccine history

 $PFD = Post$ first dose, $PSD = Post$ second dose, $PBD = Post$ booster dose, $n = Number$, $IgG =$ Immunoglobulin G, IgM = Immunoglobulin M

In Table 4, the association between age and seropositivity is shown. The proportion of participants with SARS-CoV-2 specific IgG was insignificantly higher in those between the ages of $18 - 40$ years and $41 - 59$ years compared with ≥ 60 years.

	$18 - 40$ years	$41 - 59$ years	≥ 60 years	n	X^2	<i>P</i> -value
Seronegative	$20(28.2\%)$	$9(18.4\%)$	$7(33.0\%)$	36	9.570	0.144
IgM	$0(0.0\%)$	$2(4.1\%)$	$0(0.0\%)$	2		
IgG	50 (70.4%)	$34(69.4\%)$	$12(57.1\%)$	96		
$IgM + IgG$	$1(1.4\%)$	$4(8.2\%)$	$2(9.5\%)$			

Table 4: Association between seropositivity and age groups

 $n =$ Number, IgG = Immunoglobulin G, IgM = Immunoglobulin M

Considering the association between gender and seropositivity, the proportion of male participants with SARS-CoV-2 specific IgM or IgG was not significantly different from the proportion of female participants with SARS-CoV-2 specific IgM or IgG (Table 5).

Table 5: Association between seropositivity and gender

	Male	Female	N	X^2	P-value
Seronegative	$15(26.3\%)$	21 (25.0%)	36	3.407	0.333
IgM	$2(3.5\%)$	$0(0.0\%)$	2		
IgG	38 (66.7%)	58 (69.0%)	96		
$IgM + IgG$	2(3.55)	$5(6.0\%)$			

 $n =$ Number, IgG = Immunoglobulin G, IgM = Immunoglobulin M

Discussion

The epidemiology of SARS-CoV-2 infection and its associated morbidities and mortality vary worldwide. In Nigeria, the infection and mortality rate has been relatively lower compared with many developed countries and even, some African countries. As at 27th May, 2022, the total number of confirmed cases was 256,004 while a total of 3,143 deaths were reported (27). Reasons for these observations are poorly understood but are of epidemiological importance.

The high number of individuals who never had COVID-19 test observed in this study corroborates the report of Al-Mustapha *et al*. (28). These observations showed that the true prevalence of SARS-CoV-2 infection is probably not known in Nigeria and by extension, in many African countries. In Nigeria, less than 5% of the entire population has been tested for SARS-CoV-2 infection. The NCDC report of May 27, 2022, showed that 5,160,280 Nigerians have been tested for SARS-CoV-2 infection out of over 200 million Nigerians (27). Our observed poor COVID-19 testing could be due to the myriads of challenges inundating the health system in Nigeria culminating in sub-optimal services (29). More importantly, a number of challenges are associated with molecular testing for SARS-CoV-2.

In poor resource countries, molecular testing is largely available in reference laboratories; this may result in poor access to the testing. Also, the use of molecular testing for prompt clinical decision is precluded by prolonged turnaround time. The cost of molecular testing is another important factor which could pose impediment to mass testing in low and middle income countries (30-32). Non-health system related factors could also be responsible for our observation. Lack of interest in voluntary testing in asymptomatic patients and the need for isolation, in confirmed patients, which restricts daily activities resulting in dire economic consequences.

Serological surveys have been reported to be the best tool to determine the spread of an infectious disease (33). The reports of Byambasuren *et al*. (34) and Sughayer *et al*. (35) showed that the true magnitude and spread of SARS-CoV-2 infection can be accurately reflected through seroprevalence estimates. The high proportion (66.7%) of individuals who never had COVID-19 vaccine but were seropositive for SARS-CoV-2 observed in this study supports the report of George *et al*. (36) which showed an overall seroprevalence of 62.7% in 831 vaccine naïve adults in a rural district of South India. Similarly, Murhekar *et al*. (37) reported a SARS-CoV-2 seroprevalence of 67.6% in 28,975 Indian population aged ≥6 years. They also showed that the seroprevalence was not different in rural or urban areas. Our observation, together with the previous reports, showed that the true magnitude of SARS-CoV-2 infection could be better estimated through seroepidemiological studies. In addition, observation from this study suggests that there is the need for SARS-CoV-2 specific antibody screening before vaccination in order to optimize available vaccine doses especially in poor resource countries that largely depend on vaccine donations. The use of serology tests and seroepidemiological reports in supporting immunization policies against vaccine-preventable diseases is well established (38).

Antibody levels are a relatively crude tool to assess vaccine effectiveness. However, the durability of immune protection following vaccination as compared to natural infection remains an important question (39). Anti-SARS-CoV-2 antibodies have been shown to be convenient surrogate in both vaccinated and naturally immunized individuals (40-42). Murhekar and colleagues (37) reported seroprevalence rates of 81% and 89.8% among adults who had received one dose and 2 doses of COVID-19 vaccines respectively. Similarly, Hamaya *et al*. (43) reported seroprevalence rate of 98% among healthy adults after the second dose of the BNT162b2 mRNA vaccine. Our study is in tandem with these previous studies as 69.2% and 73.8% seroprevalence rates were observed post first and second doses

of COVID-19 vaccine respectively. It could therefore be stated that more than 50% of Nigerians who had COVID-19 vaccine produced antibodies against SARS-CoV-2.

Comparing the efficacy of vaccines head-to-head is practically impossible due to a number of factors. Some of these factors include approaches taken in designing the studies, different endpoint of clinical trials, and differing case rates and circulating variants during the period of the clinical trials among others (44, 45). Reports have shown that the AstraZeneca vaccine has about 76% efficacy against symptomatic SARS-CoV-2. This efficacy is specific to events from 15 days post second-dose, with an interval dose of 29 days (45). Similarly, the Moderna vaccine has been reported to have about 94.1% efficacy against the ancestral strain of SARS-CoV-2, starting from day 14 post first-dose (46). These reports probably explain our observation that 23.1% and 21.4% of the participants who have had first and second doses of COVID-19 vaccine respectively had no detectable anti-SARS-CoV-2 antibodies. More worrisome was our observation that the only participant who has had the booster dose also had no detectable anti-SARS-CoV-2 antibodies. The report of Stringhini *et al*. (47) showed that 3 adults who have had at least one dose of COVID-19 vaccine had no detectable anti-SARS-CoV-2 antibodies after more than 14 days of vaccination. These observations are of clinical importance as they suggest that there is the need for anti-SARS-CoV-2 antibodies screening post vaccination to ensure that protection is achieved. Such screening is necessary if herd immunity is to be achieved.

In this study, majority of the participants were vaccinated with AstraZeneca (91.7%) compared with Moderna (8.3%). This observation could be due to availability. A large mass of COVID-19 vaccines administered in Nigeria were donated by several donor agencies and developed countries. It could also be due to false believes of relative severities of adverse reactions. Interestingly, results from our study showed that participants who had Astrazeneca vaccine had similar antibody response with those that took Moderna vaccine. Seven (77.8%)

of the 9 participants that took Moderna vaccine had detectable SARS-CoV-2 antibodies while 2 (22.2%) did not. Similarly, 77 (77.8%) of the 99 participants that took Astrazeneca vaccine had detectable SARS-CoV-2 antibodies while 22 (22.2%) did not.

Seroprevalence estimates have been shown to differ significantly across age groups. It was shown to be lowest among children and highest among older adults (47). Similarly, Murhekar *et al*. (37) reported that seroprevalence post-vaccination increased with age. In our study, a dissimilar pattern was observed as the proportion of participants with SARS-CoV-2 specific IgG was insignificantly higher in those between the ages of 18 and 40 years, and 41 and 59 years compared with those aged ≥ 60 years. Our observation might indicate that the immune response to the antigen contained in the vaccine is relatively lower in the elderly compared with the young adults; this possibility is in line with the immunosenescence hypothesis.Our observation is consistent with several reports which showed that relatively older COVID-19 vaccine recipients had a diminished IgG response as compared to younger recipients (48-54).

Gender was explored as a possible modifier of the vaccine response. We observed no significant association between gender and seropositivity. Keshavarz et al. (54) reported that lower IgG levels were not significantly associated with sex in recipients of BNT162b2 at day 7 - 20 post-boost.

At present, there is the dearth of information on the antibody titre threshold, induced via vaccination or natural infection, which could be considered adequate to protect an individual from SARS-CoV-2 infection. Longitudinal scale studies to determine the presence of neutralizing antibodies in vaccinated individuals are recommended.

It could be concluded from this study that there is high SARS-CoV-2 antibody seroprevalence among Nigerian adults who never had any form of COVID-19 testing. This

further confirms the erstwhile suspicion of large scale undetected community transmission. Also, it is of clinical importance to screen for anti-SARS-CoV-2 antibodies post vaccination as it could be essential in achieving herd immunity. Age and gender do not seem to have significant association with seropositivity. Information from this study could help policymakers make informed decisions regarding vaccination strategies in Nigeria.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.07.06.22277313;](https://doi.org/10.1101/2022.07.06.22277313) this version posted July 10, 2022. The copyright holder for this preprint

References

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet (London, England). 2020;395(10223):470-3.

2. Samaranayake L, Fakhruddin KS. COVID-19 vaccines and dentistry. Dental Update. 2021;48(1):76-81.

3. Olu-Abiodun O, Abiodun O, Okafor N. COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors. PloS one. 2022;17(5):e0267691.

4. Adesegun OA, Binuyo T, Adeyemi O, Ehioghae O, Rabor DF, Amusan O, et al. The COVID-19 crisis in sub-Saharan Africa: knowledge, attitudes, and practices of the Nigerian public. The American Journal of Tropical Medicine and Hygiene. 2020;103(5):1997.

5. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatric respiratory reviews. 2020;35:43-9.

6. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus research. 2020;288:198114.

7. Irwin A, Nkengasong J. What it will take to vaccinate the world against COVID-19. Nature. 2021;592(7853):176-8.

8. Nigeria Center for Disease Control. COVID-19 Nigeria Abuja: Nigeria Centre for Disease Control; Available from: https://covid19.ncdc.gov.ng/. . 2021.

9. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Overview. Available: https://covid19.who.int/. 2022.

10. Our World in Data. Coronavirus (COVID-19) Vaccinations. Available: https://ourworldindata.org/covid-vaccinations?country=NGA. 2022.

11. Brouwer PJ, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science (New York, NY). 2020;369(6504):643-50.

12. Arinola GO. Serum levels of anti-corona virus specific-IgG and-IgM antibodies in COVID-19 patients at admission and at discharge. Journal of Clinical and Experimental Medicine. 2021;19(1):5- 9.

13. Xiang T, Liang B, Fang Y, Lu S, Li S, Wang H, et al. Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset. Frontiers in immunology. 2021;12:2327.

14. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nature reviews Immunology. 2020;20(6):339-41.

15. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature medicine. 2020;26(6):845-8.

16. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183(4):996-1012.e19.

17. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020;383(18):1724-34.

18. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Reports Medicine. 2020;1(3):100040.

19. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (New York, NY). 2020;370(6521):1227-30.

20. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. 2020.

21. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science immunology. 2020;5(54):eabe0240.

22. Röltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell host & microbe. 2021;29(7):1063-75.

23. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-8.

24. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science (New York, NY). 2022;375(6576):43-50.

25. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine. 2021;27(7):1205-11.

26. World Health Organization W. Laboratory testing for coronavirus disease

(COVID-19) in suspected human cases2020 [cited 2020 July 7]. Available from: https://apps.who.int/iris/bitstream/handle/10665/331501/WHO-COVID-19-laboratory-2020.5 eng.pdf?sequence=1&isAllowed=y.

27. Nigeria Center for Disease Control. NCDC Coronavirus COVD-19 microsite. COVID-19 Nigeria, Friday 7:00 am 27 May 2022. Available: https://covid19.ncdc.gov.ng. 2022.

28. Al-Mustapha AI, Tijani AA, Oyewo M, Ibrahim A, Elelu N, Ogundijo OA, et al. Nigeria's race to zero COVID-19 cases: True disease burden or testing failure? Journal of global health. 2021;11:03094.

29. Anthonia Obi-Ani N, Ezeaku DO, Ikem O, Isiani MC, Obi-Ani P, Janefrances Chisolum O. Covid-19 pandemic and The Nigerian primary healthcare system: The leadership question. Cogent Arts & Humanities. 2021;8(1):1859075.

30. Jacobs J, Kühne V, Lunguya O, Affolabi D, Hardy L, Vandenberg O. Implementing COVID-19 (SARS-CoV-2) rapid diagnostic tests in Sub-Saharan Africa: a review. Frontiers in medicine. 2020:684.

31. Mendelson M, Madhi S. South Africa's coronavirus testing strategy is broken and not fit for purpose: it's time for a change. South African Medical Journal. 2020;110(6):429-31.

32. Sethi S, Chakraborty T. Molecular (real-time reverse transcription polymerase chain reaction) diagnosis of SARS-CoV-2 infections: complexity and challenges. Journal of Laboratory Medicine. 2021;45(3):135-42.

33. Metcalf CJ, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet (London, England). 2016;388(10045):728-30.

34. Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, McLaws M-L, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PloS one. 2021;16(4):e0248946.

35. Sughayer MA, Mansour A, Al Nuirat A, Souan L, Ghanem M, Siag M. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;107:116-20.

36. George CE, Inbaraj LR, Rajukutty S, Joan RF, Suseeladevi AK, Muthuraj S, et al. Seroprevalence of COVID-19 infection among vaccine naïve population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study. PloS one. 2022;17(3):e0265236.

37. Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Santhosh Kumar M, Selvaraju S, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study. PLoS medicine. 2021;18(12):e1003877.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.07.06.22277313;](https://doi.org/10.1101/2022.07.06.22277313) this version posted July 10, 2022. The copyright holder for this preprint

38. Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Tropical medicine & international health : TM & IH. 2016;21(9):1086-98.

39. Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet Respiratory medicine. 2021;9(12):1450-66.

40. Kadkhoda K. Herd Immunity to COVID-19. American journal of clinical pathology. 2021;155(4):471-2.

41. Arinola OG, Onifade AA, Edem VF, Yaqub SA, Rahamon SK. Elucidating the immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) infection: drivers of recovery and discovery. 2022;In Press.

42. Pandolfi S, Chirumbolo S. On reaching herd immunity during the COVID-19 pandemic and further issues. 2022;94(1):24-5.

43. Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, et al. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. Scientific reports. 2022;12(1):1-7.

44. Connelly D. Everything you need to know about COVID-19 vaccines. The Pharmaceutical Journal. 2021;306(7950):306(7950).

45. World Health Organization. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know. Available: https://www.who.int/news-room/featurestories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-

know#:~:text=how%20efficacious%20is%20the%20vaccine,dose%20interval%20of%2029%20days. 2022.

46. World Health Organization. the Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. Available: https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19 mrna-1273-vaccine-what-you-need-to-know. 2022.

47. Stringhini S, Zaballa ME, Pullen N, Perez-Saez J, de Mestral C, Loizeau AJ, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021;26(43).

48. Richards NE, Keshavarz B, Workman LJ, Nelson MR, Platts-Mills TAE, Wilson JM. Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. JAMA network open. 2021;4(9):e2124331.

49. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet regional health Europe. 2021;10:100208.

50. Collier DA, Ferreira IA, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417-22.

51. Demaret J, Corroyer-Simovic B, Alidjinou EK, Goffard A, Trauet J, Miczek S, et al. Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people. Frontiers in immunology. 2021;12.

52. Vassilaki N, Gargalionis AN, Bletsa A, Papamichalopoulos N, Kontou E, Gkika M, et al. Impact of age and sex on antibody response following the second dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms. 2021;9(8):1725.

53. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;73(11):2065-72.

54. Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al. Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Frontiers in immunology. 2022;13:850987.